Emergent BioSolutions | EBS - Selling And Administration Expenses

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $182.8M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Coherus Biosciences USD 26.02M 8.57M Mar/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Exact Sciences USD 491.64M 35.94M Sep/2025
Exelixis USD 123.02M 19.9M Dec/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pacira USD 91.8M 14.6M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Xoma USD 11M 2.54M Jun/2024